Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”
Executive Summary
Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17
You may also be interested in...
FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says
The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn
FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says
The ongoing discussions between FDA and Pfizer over Lyrica (pregabalin) undercut the argument that the agency is too soft on industry, Pfizer Worldwide Development President Joe Feczko suggested during a Nov. 30 analyst meeting in Groton, Conn
Pfizer Stops Swinging For The Fences; Combo Products Are Big Opportunity
Pfizer is investing more heavily in low-risk "product enhancements" to help round out its R&D portfolio